Screener
ArriVent BioPharma, Inc. AVBP Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
| Total other comprehensive gain (loss) | (284) | 194 |
| Total comprehensive loss | $(43,604) | $(64,193) |
| Share information: | ||
| Net loss per share attributable to common stockholders, basic and diluted | $(0.96) | $(1.90) |
| Weighted-average shares of common stock outstanding, basic and diluted | 45,067,658 | 33,898,870 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- ArriVent BioPharma, Inc. (AVBP) reported comprehensive income (loss), net of tax, attributable to parent of -$43.6M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 32.1% year-over-year, from -$64.19M to -$43.6M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 54.8% compound annual growth rate (CAGR), from -$69.33M to -$166.08M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity resulting from both net income and other comprehensive income items during a specific period. It serves as the ultimate measure of the company's total financial performance and wealth generation for shareholders. By combining operational results with non-operational valuation changes, it offers a holistic view of the company's overall financial health.
Ask your AI about ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude